Omnix Medical Raises $8.5 million for its Novel Drug Targeting AMR Bacteria
Omnix Medical just raised an additional $8.5 million to bring its promising AMR (antimicrobial resistance) drug, OMN6, for the treatment of hospital-acquired infections, to clinical
Promising Results in Immunity Pharma’s Interim Phase 1/2a IPL344 in ALS Study
The new treatment being developed by Immunity Pharma may give ALS (Lou Gehrig’s Disease) patients hope. ALS is an “orphan disease” – one that affects
Mapi Pharma In Talks To Produce Covid-19 Vaccine in Jerusalem
Israeli drug development company Mapi Pharma announced today that it will dedicate capacity at its manufacturing facility in Jerusalem’s Har Hotzvim industrial park to produce
FIMI Buys Rafa Laboratories for NIS 700m Valuation
FIMI Opportunity Funds has acquired from the Sackler family a 90% stake in Israeli pharmaceutical company Rafa Laboratories Ltd. at a company valuation of NIS 700
Cell Therapy QC Company, Accellix, Raised $9.5 Million in Series D Round
Jerusalem based, Accellix, the Cell Therapy QC company, had a Series D financing round of $9.5 million led by bioMérieux, a world leader in the
Hadassah to Conduct Clinical Trial of Israeli-Made COVID-19 Vaccine
The Hadassah Medical Organization is slated to begin a clinical trial with an Israeli-made COVID-19 vaccine in October. One hundred volunteers are being recruited to
MYOR Begins US Commercialization of its Breakthrough Platform to Prevent Allergic Conditions
MYOR‘s NURTURE Precision Infant Care enables prevention of food allergies and atopic dermatitis via early prediction in newborns. NURTURE, a clinical decision support tool, provides
Enlivex’s Experimental Allocetra Drug Saves Five Covid Patients at Hadassah Hospital
Hadassah Hospital released five fully recuperated patients who were in critical condition with coronavirus, due to their treatment with the experimental drug, Allocetra developed by
Novellus Raises $57M!
Novellus, Ltd., a Jerusalem-based clinical-stage biotechnology company focused on precision oncology and cancer treatment, raised $ 57 million in a Series C financing round in
